While current studies in Duchenne muscular dystrophy (DMD) mainly explore gene and exon-skipping therapies, other options might exist in drugs already on the…
Articles by Magdalena Kegel
Current drug development approaches for muscular dystrophy have focused mainly on loss of walking ability and do little for heart…
Mice lacking the immunomodulatory protein osteopontin have fewer Duchenne muscular dystrophy (DMD) symptoms, a finding researchers attributed to a switch in…
Marathon Pharmaceuticals recently presented additional results from a Phase 3 clinical trial of deflazacort, an investigational glucocorticoid corticosteroid that the company hopes…
Duchenne muscular dystrophy (DMD) patients at more advanced disease stages, those reliant on wheelchairs, showed improved lung function when treated with deflazacort…
The glucocorticoid deflazacort might shortly be approved for treatment of Duchenne muscular dystrophy (DMD) in the US. In preparation for…
The only drugs currently recommended for people with Duchenne muscular dystrophy (DMD) are glucocorticoid corticosteroids, but many patients still do not…
For older boys with Duchenne muscular dystrophy (DMD), the time it takes to rise from the floor is associated with disease…
Researchers at MDI Biological Laboratory in Maine have discovered new mechanisms in heart tissue regeneration. The findings, published in the…
Recent advances in gene-editing technologies allow for precise manipulation of the genome to achieve therapeutic effects. While challenges remain, genome…